The US FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.1 billion market cap biopharmaceutical company with impressive 91% gross profit margins, has reached a settlement agreement with Teva ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue ...